Fixed Combination for the Treatment of Dyslipidaemia

被引：0
|
作者：
Nicola Ferri
Massimiliano Ruscica
Raul D. Santos
Alberto Corsini
机构：
[1] University of Padova,Department of Medicine (DIMED)
[2] Veneto Institute of Molecular Medicine (VIMM),Department of Pharmacological and Biomolecular Sciences “Rodolfo Paoletti”
[3] University of Milan,Lipid Clinic, Heart Institute (InCor)
[4] Department of Cardio-Thoracic-Vascular Diseases – Foundation IRCCS Cà Granda Ospedale Maggiore Policlinico,undefined
[5] University of São Paulo,undefined
[6] Hospital Israelita Albert Einstein,undefined
来源：
Current Atherosclerosis Reports | 2023年 / 25卷
关键词：
Statins; Bempedoic acid; Ezetimibe; Fenofibrate; Combinations; Polypill;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：691 / 699
页数：8
相关论文
共 50 条
  • [31] Controversies in dyslipidaemia management
    Stock, Jane
    ATHEROSCLEROSIS, 2012, 221 (02) : 321 - 324
  • [32] The effects of simvastatin treatment on plasma lipid-related biomarkers in men with dyslipidaemia
    Chen, Fabian
    Maridakis, Vic
    O'Neill, Edward A.
    Hubbard, Brian K.
    Strack, Alison
    Beals, Chan
    Herman, Gary A.
    Wong, Peggy
    BIOMARKERS, 2011, 16 (04) : 321 - 333
  • [33] Pharmacokinetic non-interaction analysis in a fixed-dose formulation in combination of atorvastatin and ezetimibe
    Patino-Rodriguez, Omar
    Torres-Roque, Irma
    Martinez-Delgado, Maricela
    Escobedo-Moratilla, Abraham
    Perez-Urizar, Jose
    FRONTIERS IN PHARMACOLOGY, 2014, 5
  • [34] Trends in Ezetimibe Prescriptions as Monotherapy or Fixed-Dose Combination in Germany 2012-2021
    Katzmann, Julius L.
    Kieble, Marita
    Enners, Salka
    Boehm, Michael
    Mahfoud, Felix
    Laufs, Ulrich
    Schulz, Martin
    FRONTIERS IN CARDIOVASCULAR MEDICINE, 2022, 9
  • [35] The effect of hypolipidaemic treatment on monocyte release of proinflammatory cytokines in different age groups of patients with type 2 diabetes and atherogenic dyslipidaemia
    Krysiak, Robert
    Gdula-Dymek, Anna
    Marek, Bogdan
    Okopien, Boguslaw
    ENDOKRYNOLOGIA POLSKA, 2016, 67 (02) : 190 - 196
  • [36] 'Multiple action fixed combination. Present or future?'
    Antonio Garcia-Donaire, Jose
    Miguel Ruilope, Luis
    FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2010, 24 (01) : 37 - 42
  • [37] The fixed combination of pravastatin and fenofibrate: What can it provide?
    Diaz Rodriguez, Angel
    CLINICA E INVESTIGACION EN ARTERIOSCLEROSIS, 2014, 26 : 12 - 16
  • [38] An overview of childhood dyslipidaemia
    Schellack, G.
    Schellack, N.
    Malan, L.
    SA PHARMACEUTICAL JOURNAL, 2016, 83 (07) : 38 - 42
  • [39] Effect of rosuvastatin or its combination with omega-3 fatty acids on circulating CD34+ progenitor cells and on endothelial colony formation in patients with mixed dyslipidaemia
    Chantzichristos, Vasileios G.
    Agouridis, Aris P.
    Moutzouri, Elisavet
    Stellos, Konstantinos
    Elisaf, Moses S.
    Tselepis, Alexandros D.
    ATHEROSCLEROSIS, 2016, 251 : 240 - 247
  • [40] Rosuvastatin: a highly efficacious statin for the treatment of dyslipidaemia (vol 11, pg 125, 2002)
    Davidson, MH
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2002, 11 (03) : 455 - +
12345